Načítá se...
P01.035 Nivolumab and Temozolomide (TMZ) vs TMZ alone in newly diagnosed elderly patients (pts) with Glioblastoma (GBM) (NUTMEG): Trial in progress
BACKGROUND: TMZ with short course radiotherapy (RT) is an option for elderly GBM patients. Nivolumab is a PD-1 inhibitor with known safety profile in GBM. An increase of mutations as we age is well documented in GBM and in cancer in general. A higher mutational load is associated with increased resp...
Uloženo v:
| Vydáno v: | Neuro Oncol |
|---|---|
| Hlavní autoři: | , , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Oxford University Press
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6144427/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy139.077 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|